Sangamo Therapeutics Receives U.S. FDA Fast Track Designation For Isaralgagene Civaparvovec For The Treatment Of Fabry Disease
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics has received Fast Track Designation from the U.S. FDA for its gene therapy product candidate, isaralgagene civaparvovec (ST-920), for the treatment of Fabry disease. The designation aims to expedite the development and review of new therapeutics for serious conditions with unmet medical needs.
May 22, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sangamo Therapeutics' ST-920 receives FDA Fast Track Designation for Fabry disease treatment, potentially expediting its development and review.
The FDA Fast Track Designation for Sangamo's ST-920 is a positive development for the company, as it may expedite the development and review process for the gene therapy candidate. This could potentially lead to faster market entry and revenue generation for Sangamo, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100